2022 Volume 22 Issue 2 Pages 49-53
In Japan, olaparib (Lynparza®), a therapeutic drug against the BRCA gene in the germline was approved for patients with breast cancer in July 2018. BRACAnalysis CDx®is a companion diagnosis that has been initiated to determine the indication of olaparib. In this study, we report the challenges encountered by oncology certified nurse specialists in cancer nursing (hereinafter referred to OCNS) and the issues in and prospects for cancer genome medicine in a 482-bed general hospital with a history of HBOC genetic counseling in the process of implementing BRACAnalysis CDx®.
